Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an underwritten
Aclaris raised $50 million by selling new shares and warrants to investors. When a company needs to raise money this way, watch if the stock price stays steady or drops after.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.